MedTrace Logo

Adjuvant Low Dose Aspirin in Colorectal Cancer

NCT02647099 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 626

Last updated 2026-03-13

Study results available
· View outcomes & findings →

Summary

ALASCCA is a randomized, parallel group, double blind, multicenter, placebo-controlled, biomarker-based study of adjuvant treatment with low dose aspirin in patients with colorectal cancer. Hypothesis is that patients diagnosed with colorectal cancer and somatic mutations in PI3K pathway can significantly improve survival if treated with low dose aspirin.

Conditions

Interventions

DRUG

Acetylsalicylic acid

DRUG

Placebo

Sponsors & Collaborators

  • Uppsala University Hospital

    collaborator OTHER

  • Skane University Hospital

    collaborator OTHER

  • Anna Martling

    lead OTHER

Principal Investigators

  • Anna Martling, Professor · Karolinska Institutet

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-07
Primary Completion
2024-08-31
Completion
2026-08-31

Countries

  • Denmark
  • Finland
  • Norway
  • Sweden

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02647099 on ClinicalTrials.gov